Tasco's Bio-Matrix Scientific Unit Installs New, Cutting-Edge Stem Cell Technology in Preparation for Anticipated September 2006 Grand Opening of Its Stem Cell Cryogenic Banking and Processing Facility.

SAN DIEGO -- To Utilize Liquid Nitrogen Vapor Tanks for Storage Testing; Revenues Anticipated in 4th Quarter of 2006

Tasco Holdings International's (OTCBB:THII) wholly-owned subsidiary Bio-Matrix Scientific Group, Inc. (a Nevada corporation), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today that it has received and installed a CBS Isothermal liquid nitrogen vapor storage tank and a K Series cryo-storage tank for stem cell storage.

As Bio-Matrix builds its state-of-the-art stem cell research and storage facility in San Diego, California, the Company will utilize the new CBS V5000 cryo-tank as the flagship for cellular storage at the facility. This new technology will validate central liquid nitrogen supply that feeds all units housed at the Bio-Matrix facility.

"An investment in this new, V-5000 Isothermal Liquid Nitrogen tank and K Series tank allows Bio-Matrix to enter into system testing, which will lead to accepting stem cell storage. This is an important step toward establishing the Company's Good Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP) quality systems which is an important part of our facility master validation plan that will enhance our ability to provide superior stem cell storage over the long term," said Bio-Matrix Scientific Group Managing Director and COO Brian Pockett.

A Company spokesperson said the Company expects to open the facility for business by the end of September 2006, anticipating revenue in the 4th Quarter of 2006.

Bio-Matrix's new 15,000-sq.-ft., state-of-the-art facility, located in the heart of San Diego, will house the nation's premiere center for stem cell storage, including: Bio-Matrix's secure Cryogenic Stem Cell Bank; four research laboratories; aseptic cellular/tissue processing rooms; and hematology, microbiology and flow cytometry laboratories.

This press release is available on the Company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail], where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About Bio-Matrix Scientific Group, Inc.

Bio-Matrix Scientific Group, Inc. researches, develops and commercializes medical devices and monitoring systems in the stem cell research industry. The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation.

For more information, visit: www.BMXGonline.com and www.THII.net

DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.